期刊文献+

联合常规实验室检查指标诊断骨髓增生异常综合征的初步研究 被引量:4

Preliminary study of diagnosis of patients with myelodysplastic syndromes by routine laboratory parameters
原文传递
导出
摘要 目的探讨联合常规实验室检查指标在骨髓增生异常综合征(MDS)的诊断和低增生性MDS与慢性再生障碍性贫血(CAA)鉴别诊断中的价值,提供基层单位适用的MDS诊断和鉴别诊断参考方案。方法回顾性分析骨髓原始细胞小于0.050的152例MDS患者和86例CAA患者初诊的常规实验室检查资料并进行统计学分析。结果MDS患者血红蛋白,红细胞体积分布宽度一变异系数、未成熟网织细胞比率、血小板计数(BPC)、骨髓原始细胞及早幼粒细胞之和与中性中幼粒细胞及中性晚幼粒细胞之和的比值(RatioG)、原始红细胞及早幼红细胞之和与中幼红细胞及晚幼红细胞之和的比值(RatioE)、巨核细胞计数(Meg)、有核红细胞糖原染色(PAS)阳性率和阳性指数、中性粒细胞碱性磷酸酶染色(N—ALP)阳性率和阳性指数、血清间接胆红素(IBIL)、乳酸脱氢酶(LDH)、尿酸(UA)、叶酸(FA)、维生素B12(VitB12)、铁蛋白(SF)水平等常规实验室指标与CAA患者比较差异有统计学意义。MDS组患者有染色体核型异常者为74例(48.7%),CAA组患者染色体核型均正常,两组比较差异有统计学意义(P〈0.01)。MDS组与CAA组患者均有骨髓干/祖细胞培养生长不良或不生长,均有患者出现外周血T细胞亚群比例改变,两组比较差异无统计学意义。染色体核型异常的74例MDS患者与骨髓活检结果支持CAA诊断的82例患者(CAA组-2)比较,前述差异有统计学意义的指标均仍有统计学差异。7例骨髓低增生性MDS与CAA组-2患者比较,BPC、Meg、骨髓原始粒细胞百分比(MBP)、RatioG、有核红细胞PAS阳性率和阳性指数以及血清FA水平差异有统计学意义。选取各项差异有统计学意义的常规实验室指标进行联合诊断MDS及低增生性MDS特异度〉85%,灵敏度〉70%,正确诊断指数〉0.70。结论联合BPC、RatioG、Meg、有核红PAS阳性率和阳性指数、血清IBIL水平等常规实验室检查指标有助于MDS诊断和低增生性MDS与CAA的鉴别诊断。 Objective To explore the value of routine laboratory parameters in diagnosis of myelodysplastic syndromes(MDS) and differential diagnosis of patients with hypoplastic MDS from chronic aplastic anemia(CAA) for providing reference standard for primary hospitals. Methods The laboratory parameters at diagnosis of 152 MDS patients with less than 0.05 bone marrow blasts and 86 CAA patiens were retrospectively analyzed. Results There were significant differences between MDS and CAA in Hb, red cell distribution width-coefficient variation( RDW-CV), immature reticulocyte fraction(IRF), BPC, the ratio of G1 (the sum percentage of myeloblast and premyelocyte) to G2 ( the sum percentage of neutrophilic myelocyte and metamyelocyte) ( RatioG), the ratio of E1 ( the sum percentage of proerythroblast and early erythroblast) to E2 ( the sum percentage of intermediate erythroblast and late erythroblast) (RatinE), megakaryocyte count (Meg), erythroblast PAS, neutrophil alkaline phosphatase( N-ALP), and serous levels of indirect bilirubin (IBIL), lactose dehydrogenase (LDH), folic acid(FA), VitB12 and ferritin. Chromosome abnormalities were found in 74 MDS patients (48.7%) but in none of CAA patients ( P 〈 0.001 ). Furthermore, for differentiating MDS with less than 0.05 blasts from CAA, the sensitivity and specificity of combination of Meg, PAS, and IBIL level was 89.1% and 92.7%, the Youden index(γ) was 0. 818. Moreover, in the seven hypoplastic MDS cases, BPC, myeloblast percentage, RatioG, Meg, erythroblast PAS and FA were statistically different from those of CAA; the sensitivity and specificity of combination of PAS and BPC was 85.7% and 100%, the γ was 0. 857; the sensitivity and specificity combination of RatioG, Meg PAS was 85.7% and 98.8% respectively, the γ, was 0. 845. Conclusion The routine laboratory parameters, especially BPC, Meg, RatioG, PAS, IBIL may be halpful for the diagnosis of MDS and differential diagnosis of hypoplastic MDS from CAA.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2008年第9期623-628,共6页 Chinese Journal of Hematology
基金 国家自然科学基金(30670899) 高等学校博士学科点专项科研基金(20050023033) 新世纪优秀人才资助计划(NCET-05-0173) 天津市自然科学基金重点项目(08JCZDJC19200)
关键词 骨髓增生异常综合征 低增生性 贫血 再生障碍性 诊断 Myelodysplastic syndromes, hypoplastic Aplastic anemia Diagnosis
  • 相关文献

参考文献11

  • 1郝洪波,肖志坚.不典型骨髓增生异常综合征的诊断[J].白血病.淋巴瘤,2005,14(2):121-123. 被引量:3
  • 2Maciejewski JP, O'Keefe C, Gondek L, et al. Immune-mediated bone marrow failure syndromes of progenitor and stem cells : molecular analysis of cytotoxic T cell clones. Folia Histochem Cytobiol, 2007,45:5-14.
  • 3肖志坚,郝玉书.骨髓增生异常综合征的诊断分型与预后判断及疗效标准[J].中华内科杂志,2002,41(12):846-848. 被引量:50
  • 4肖志坚.骨髓增生异常综合征的诊断和治疗认识现况[J].国际输血及血液学杂志,2007,30(1):1-4. 被引量:9
  • 5Corey SJ, Minden MD, Barber DL, et al. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer, 2007,7:118-129.
  • 6Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood, 2006, 108:2509-2519.
  • 7Nosslinger T, Reisner R, Koller E, et al. Myelodysplastic syndromes, from French-American- British to World Health Organization : comparison of classifications on 431 unselected patients from a single institution. Blood,2001,98:2935-2941.
  • 8Tichelll A, Gratwohl A, Nissen C, et al. Morphology in patients with severe aplastie anemia treated with antilymphoeyte globulin. Blood, 1992,80:337- 345.
  • 9Maschek H, Kaloutsi V, Rodrignez-Kaiser M, et al. Hypoplastic myelodysplastic syndrome : incidence, morphology, cytogeneties, and prognosis. Ann Hematol, 1993,66 : 117-122.
  • 10Orazi A, Albitar M, Heerema NA, et al. Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anemia by CD34 and PCNA immunostaining of bone marrow biopsy specimens. Am J Clin Pathol,1997 ,107 :268-274.

二级参考文献51

  • 1肖志坚,郝玉书.儿童骨髓增生异常综合征的诊断分型[J].中华儿科杂志,2005,43(7):545-547. 被引量:7
  • 2肖志坚.重视和加强我国儿童骨髓增生异常综合征的研究[J].中国小儿血液,2005,10(3):97-98. 被引量:6
  • 3肖志坚.骨髓增生异常综合征:现况与问题[J].白血病.淋巴瘤,2005,14(4):193-196. 被引量:31
  • 4Cachia P G, Taylor C, Thompson P W. Nondysplastic myelodysplasia [J]. Leukemia,1994, 8(4):677-681.
  • 5Anttila P, Ihalainen J, Salo A, et al. Idiopathic macrocytic anaemia in the aged:molecular and cytogenetic findings [J]. Br J Haematol, 1995, 90(4):797-803.
  • 6Steensma D P, Dewald G W, Hodnefield J M,et al. Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia[J]. Leuk Res,2003, 27(3):235 -242.
  • 7Bain B J. The bone marrow aspirate of healthy subjects[J]. Br J Haematol, 1996, 94(1):206-209.
  • 8Ramos F, Fernandez-Ferro S, Suarez D, et al.myelodysplastic syndrome: a search for minimal diagnostic criteria[J]. Leuk Res, 1999, 23(3):283 -290.
  • 9Hasle H, Niemeyer C M, Chessells J M, et al.A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases[J]. Leukemia, 2003, 17(2):277-282.
  • 10Tuzuner N, Cox C, RoweJ M, et al. Hypocellular myelodysplastic syndromes (MDS): newproposals[J]. Br J Haematol, 1995,91(3):612-617.

共引文献59

同被引文献22

  • 1王小钦,林果为.282例原发性骨髓增生异常综合征诊断和分型的前瞻性临床研究[J].中华血液学杂志,2006,27(8):546-549. 被引量:34
  • 2姚尔固.新编白血病化疗学[M].天津:天津科学技术出版社,1998:232.
  • 3张之南.血液病诊断与疗效标准[M].2版.北京:科学技术出版社,1998:214-263.
  • 4Nimer SD. Myelodysplastie syndromes. Blood,2008,111:4841- 4851.
  • 5Steven HS, Campo E, Harris NL,et al. WHO classification of tumours of haematopoictic mad lymphoid tissues. Lyon: IARC Press, 2008:88- 99.
  • 6Verburgh E, Achren R, Louw VL. A new diseaseeate-gorization of low grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification. Leukemia, 2007, 21: 668-677.
  • 7Platzbecker U, Santini V, Mufti GJ, et al. Update ondevelopments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): consensus statements and report from an expert workshop [J]. Leuk Res, 2012,36(3):264-270.
  • 8Mufti GJ, Bennett JM, Goasguen J, et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts[J]. Haematologica, 2008,93(11):1712-1717.
  • 9Naqvi K, Jabbour E, Bueso-Ramos C, et al. Implications of discrepancy in morphologic diagnosis of myelodyspla- stic syndrome between referral and tertiary care centers[J]. Blood, 2011,118(17):4690-4693.
  • 10Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastie syndromes: Consensus statements and report from a working conference[J]. Leuk Res, 2007,31 (6):727-736.

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部